MedTrace Logo

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

NCT06736613 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-12-18

No results posted yet for this study

Summary

The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test negative for CNS involvement using standard tests. The study will also look at how often CNS relapse happens in people with and without detected CSF ctDNA.

Conditions

  • Diffuse Large B Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Stage III High Grade B-Cell Lymphoma
  • Stage IV High Grade B-Cell Lymphoma
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Intravascular Large B-Cell Lymphoma
  • Diffuse Large B Cell Lymphoma of Breast
  • Diffuse Large B Cell Lymphoma of Testis
  • HIV-associated Diffuse Large B Cell Lymphoma
  • Double Expressor DLBCL

Interventions

DIAGNOSTIC_TEST

Cerebral Spinal Fluid ctDNA

MSK's Diagnostic Molecular Pathology core has developed and validated a CSF ctDNA assay which has been approved by New York State Department of Health as of 2019

Sponsors & Collaborators

Principal Investigators

  • Jennifer Lue, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-11
Primary Completion
2027-12-11
Completion
2027-12-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06736613 on ClinicalTrials.gov